SSA
SRRA

Schonfeld Strategic Advisors’s Sierra Oncology, Inc. Common Stock SRRA Stock Holding History

Schonfeld Strategic Advisors’s Portfolio SRRA Stock Details SRRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-126,500
Closed -$4.05M – 3303
2022
Q1 		$4.05M Buy
+126,500
New +$3.63M 0.04% 500
2018
Q2 		– Sell
-5,910
Closed -$489K – 1040
2018
Q1 		$489K Buy
+5,910
New +$670K 0.04% 480

Other funds holding SRRA

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VI
Versor Investments New York $40.8M AUM 93.59% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TAL
TIG Advisors LLC New York $2.16B AUM 72.99% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Schonfeld Strategic Advisors's SRRA Position: Q2 2022 in Review

Schonfeld Strategic Advisors sold out of Sierra Oncology, Inc. Common Stock (SRRA) in Q2 2022, closing a stake of 126,500 shares — an estimated $4.05M sold.

Schonfeld Strategic Advisors first reported a position in SRRA in Q1 2018 and held it in 2 quarters. The position peaked at $4.05M in Q1 2022. 109 funds tracked by Wall St. Rank hold SRRA as of Q2 2022.

  • Schonfeld Strategic Advisors reported no remaining Sierra Oncology, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 126,500 Sierra Oncology, Inc. Common Stock shares in Q2 2022, an estimated $4.05M.
  • Schonfeld Strategic Advisors first reported a position in Sierra Oncology, Inc. Common Stock in Q1 2018 and held it in 2 quarters.
  • Schonfeld Strategic Advisors's Sierra Oncology, Inc. Common Stock position peaked at $4.05M in Q1 2022.
  • 109 funds tracked by Wall St. Rank held Sierra Oncology, Inc. Common Stock as of Q2 2022.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2022, filed 15 Aug 2022.